title: Epilepsy biomarkers.
abstract: A biomarker is defined as an objectively measured characteristic of a normal or pathologic biologic process. Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the presence and severity of tissue capable of generating spontaneous seizures; measure progression after the condition is established; and determine pharmacoresistance. Such biomarkers could be used to create animal models for more cost-effective screening of potential antiepileptogenic and antiseizure drugs and devices, and to reduce the cost of clinical trials by enriching the trial population, and acting as surrogate markers to shorten trial duration. The objectives of the biomarker subgroup for the London Workshop were to define approaches for identifying possible biomarkers for these purposes. Research to identify reliable biomarkers may also reveal underlying mechanisms that could serve as therapeutic targets for the development of new antiepileptogenic and antiseizure compounds.
authors.affiliation: Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1769, USA. engel@ucla.edu
authors.forename: Jerome
authors.initials: J
authors.lastname: Engel
authors.forename: Asla
authors.initials: A
authors.lastname: Pitkänen
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Loeb
authors.forename: F Edward
authors.initials: FE
authors.lastname: Dudek
authors.forename: Edward H
authors.initials: EH
authors.lastname: Bertram
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Cole
authors.forename: Solomon L
authors.initials: SL
authors.lastname: Moshé
authors.forename: Samuel
authors.initials: S
authors.lastname: Wiebe
authors.forename: Frances E
authors.initials: FE
authors.lastname: Jensen
authors.forename: Istvan
authors.initials: I
authors.lastname: Mody
authors.forename: Astrid
authors.initials: A
authors.lastname: Nehlig
authors.forename: Annamaria
authors.initials: A
authors.lastname: Vezzani
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D001921:Brain / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000191:economics; D003362:Cost-Benefit Analysis; D004195:Disease Models, Animal; D018450:Disease Progression; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical / Q000191:economics; D004351:Drug Resistance; D015507:Drugs, Investigational / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D015985:Precipitating Factors
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D015507:Drugs, Investigational
keywords: Biomarkers; Epileptogenesis; Ictogenesis; Surrogate markers; Therapeutic intervention
references.citation: Biomark Med. 2011 Oct;5(5):577-84
references.pmid: 22003906
references.citation: J Clin Neurophysiol. 2010 Dec;27(6):372-9
references.pmid: 21076336
references.citation: Neurosci Lett. 2011 Jun 27;497(3):205-12
references.pmid: 21382442
references.citation: Biomark Med. 2011 Oct;5(5):537-44
references.pmid: 22003902
references.citation: Biomark Med. 2011 Oct;5(5):615-28
references.pmid: 22003910
references.citation: Epilepsia. 2010 Apr;51(4):676-85
references.pmid: 20196795
references.citation: Epilepsia. 2010 Jul;51 Suppl 3:171-7
references.pmid: 20618426
references.citation: NeuroRx. 2004 Apr;1(2):189-95
references.pmid: 15717019
references.citation: Epilepsia. 2007;48 Suppl 5:86-95
references.pmid: 17910586
references.citation: Biomark Med. 2011 Oct;5(5):557-66
references.pmid: 22003904
references.citation: Biomark Med. 2011 Oct;5(5):545-56
references.pmid: 22003903